Mesna (Mesnex) Market

Global Mesna (Mesnex) Market Size, Share, and Trend Analysis Report, By Type (Oral and Injection), By Application (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025462 | Category : Pharmaceuticals | Delivery Format: /

The global mesna (mesnex) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to boost the market growth include an increase in incidences of cancer, coupled with the rising practices of chemotherapy, which has increased the demand for mesna. In 2018, cases of cancer were estimated to be 1,735,350 and this figure is estimated to grow by 3% every year. As a result, the chemotherapy is going through a phase of evolution and rapid progress. Ongoing clinical research for use in new treatment such as hemorrhagic cystitis is another factor that is accelerating the growth of the market along with increasing approvals by the FDA for new therapies, which are expected to open new doors for mesna. 

Mesnex is sold by the trade name mesna. It is a thiol compound that oxidizes rapidly in plasma to mesna disulfide, it is hydrophilic, remains in the intravascular compartment, and is rapidly thrown by the kidneys. Mesna is a drug used for the prevention of ifosfamide-induced hemorrhagic cystitis and high-dose cyclophosphamide-induced hemorrhagic cystitis. It is also prescribed after the chemotherapy to reduce the undesired side effects of certain chemotherapy drugs. It is either injected through the vein or given as a pill by mouth. Mesna is either consumed as a tablet or injected into the veins in a dosage equal to 40% of the ifosfamide dose at two and six hours after each dose of ifosfamide as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis in conjunction with standard antineoplastic therapy. The daily dose of mesna is equal to 100% of the ifosfamide dose. 

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape: Sagent Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, and Baxter International Inc., among others. 

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Mesna (Mesnex) Market Report Segmentation

By Type 

Oral 

Injections

By Application 

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Mesna (Mesnex) Market by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World